Imagine trying to track a fire using an old map when you actually have a high-tech thermal camera available. This project replaces outdated CT scans with a more precise imaging tool called FDG-PET/CT to see exactly how breast cancer is responding to treatment. By involving patients in the process, they are creating a modern digital roadmap for care that helps doctors make faster, more accurate decisions.
Cancer response monitoring has not been updated in decades, relying on outdated CT scans. This leads to suboptimal treatment adjustments and lower survival rates for patients with metastatic breast cancer.
A multicenter clinical trial comparing FDG-PET/CT to CT, digital workflows for patient pathways, and AI-based imaging and liquid biopsy tools.
If you are a manufacturer dealing with stagnant CT scan demand — this project developed FDG-PET/CT-based monitoring protocols that provide higher accuracy for metastatic breast cancer. This creates a clear clinical justification for hospitals to upgrade to molecular imaging hardware.
If you are a software company dealing with fragmented oncology workflows — this project developed digital workflows and AI-based imaging solutions. These tools streamline how doctors track cancer response, reducing manual errors in patient pathways.
If you are a diagnostics firm dealing with a lack of clinical validation for new tests — this project developed a pragmatic multicenter trial including liquid biopsies. This provides the evidence needed to integrate blood-based monitoring into standard cancer care.
The project includes cost-effectiveness analyses specifically designed to inform health policymakers and HTA agencies. Based on available project data, the exact price points are not yet listed.
The project uses a multicenter randomised clinical trial across 7 countries. This provides a scalable model for clinical implementation across different European healthcare systems.
Based on available project data, there is no specific mention of patents or licensing agreements, as the project focuses on clinical recommendations and digital workflows.
The project aims to provide knowledge for updated international recommendations for response evaluation in metastatic breast cancer. This evidence is intended to guide clinical implementation and policy changes.
The project period runs from 2024-01-01 to 2029-12-31, suggesting a long-term validation and implementation phase.
The consortium is heavily weighted toward academic and public research, with 6 universities and 2 research institutes. However, it includes 1 industry partner and 4 other organizations across 7 countries, indicating a strong clinical validation network. The 8% industry ratio suggests the project is currently in the evidence-generation phase rather than the commercial-scaling phase.
Contact REGION SYDDANMARK in Denmark
Contact us to connect with the PREMIO COLLAB consortium for AI imaging integration.
